Viatris’ second-quarter results were met with a negative market reaction, despite the company surpassing Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s performance to strong commercial execution in Greater China, where investments in established brands and e-commerce channels drove double-digit growth. CEO Scott Smith emphasized that demand for cardiovascular products and the company’s strategic focus on higher-margin generics in North America contributed meaningfully, while supply chain disruptions and lower-margin product headwinds in emerging markets weighed on results.
Is now the time to buy VTRS? Find out in our full research report (it’s free for active Edge members).
Viatris (VTRS) Q2 CY2026 Highlights:
- Revenue: $3.76 billion vs analyst estimates of $3.68 billion (4.9% year-on-year growth, 2.2% beat)
- Adjusted EPS: $0.69 vs analyst estimates of $0.60 (15% beat)
- Adjusted EBITDA: $1.19 billion vs analyst estimates of $1.08 billion (31.6% margin, 10.3% beat)
- The company slightly lifted its revenue guidance for the full year to $14.75 billion at the midpoint from $14.7 billion
- Management raised its full-year Adjusted EPS guidance to $2.52 at the midpoint, a 5% increase
- EBITDA guidance for the full year is $4.4 billion at the midpoint, in line with analyst expectations
- Operating Margin: 0.2%, down from 6.5% in the same quarter last year
- Market Capitalization: $18.49 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Viatris’s Q2 Earnings Call
- Ashwani Verma (UBS) asked about the durability of China’s growth and e-commerce contribution. CEO Scott Smith outlined channel diversity and demand resilience, while CFO Paul Campbell detailed e-commerce comprises 10-15% of the China business.
- Umer Raffat (Evercore) inquired about selatogrel’s clinical trial design and patient management. Chief R&D Officer Philippe Martin explained the enrollment strategy and clinical rationale for trial endpoints and patient transitions.
- Matthew Dellatorre (Goldman Sachs) queried the commercial potential of fast-acting meloxicam and selatogrel. CEO Scott Smith and Chief Commercial Officer Corinne Le Goff projected strong uptake if approved, with meloxicam potentially reaching $500 million in peak sales.
- Glen Santangelo (Barclays) asked about the impact and duration of manufacturing disruptions and policy changes in China. Management indicated supply issues are expected to be short term, fully reflected in guidance, and that China’s policy effects will become clearer later in the year.
- Yuchen Ding (Jefferies) probed cenerimod’s clinical data and the rationale for trial design adjustments. Chief R&D Officer Philippe Martin elaborated on targeting high-interferon patients and endpoint improvements to bolster efficacy signals.
Catalysts in Upcoming Quarters
In coming quarters, the StockStory team will be closely monitoring (1) the commercial launch and uptake of fast-acting meloxicam and Gwyn Lo, (2) the resolution of manufacturing disruptions at the Nashik facility and associated supply chain impacts, and (3) the evolving policy environment in China and its effect on hospital channel sales. Progress on pipeline milestones and clarity on business development initiatives will also be key signposts for execution.
Viatris currently trades at $16.32, down from $17.65 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
